top of page

Latest News

Inhalon Biopharma to Present on Product Development Pipeline at Biotech Showcase

Durham, North Carolina, January 8, 2024 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at Biotech Showcase on January 9, 2024, in San Francisco, CA. During the company’s presentation, president and chief executive officer John Whelan will discuss the company’s pipeline for inhaled treatments for acute respiratory infections.


The Company is developing products for the treatment of respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza based on its inhaled antibody platform. Its treatment approach involves the delivery of antibodies directly to the site of infection via inhalation. Inhaled administration is convenient and offers the potential to reduce costs and ease the burden of care on patients and the health care system.


“Our platform offers the potential to treat a variety of acute respiratory infections by self-administering antibodies via a handheld, portable nebulizer. We look forward to sharing more about our initial clinical data and our development activities,” said John Whelan, president and chief executive officer at Inhalon Biopharma. “We aim to deliver treatments that are easier to administer, store, and distribute compared to antibodies designed for intravenous delivery, and likely to be preferred by patients.”


Inhalon Biophama recently announced an hMPV licensing deal with the University of Georgia and secured a U.S. Army Medical Research and Development command award to support the development of its treatments for COVID-19.



Biotech Showcase Presentation Details

Date: Tuesday, January 9, 2024

Time: 10:30 a.m. PDT

Track: Franciscan A (Ballroom Level) at the Hilton San Francisco Union Square


About Inhalon Biopharma

Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC.



For General Inquires

John Whelan



Gwen Gordon

bottom of page